Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma

BACKGROUND: In the U.K. Medical Research Council Myeloma IX trial (mmix), zoledronic acid 4 mg once every 3–4 weeks, compared with clodronate 1600 mg daily, reduced the incidence of skeletal related events (sres), increased progression-free survival (pfs), and prolonged overall survival (os) in 1970...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Delea, T.E., El Ouagari, K., Rotter, J., Wang, A., Kaura, S., Morgan, G.J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Multimed Inc. 2012
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3503670/
https://ncbi.nlm.nih.gov/pubmed/23300363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.1004
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi